Login / Signup
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
Send us Feedback
Eli Lilly and Company (LLY)
SUMMARY
BULLS
BEARS
DATA CENTRAL
STOCK CHART
OPERATING METRICS
REVENUE SOURCES
BALANCE SHEET
INCOME STMT
CASH FLOW
Key Metrics for LLY as compared to
Top Competitors
Drug Manufacturers - Major
Drug Manufacturers
Pharma & Healthcare
All values TTM unless otherwise noted (*)
INDUSTRY METRICS (
See all
)
Revenue
►
21.1B
AVG
R&D Expense
►
3.84B
AVG
R&D/Sales Ratio
►
18.9%
AVG
Expiring Patents
►
5.00
LOW
Number of Drugs
►
60.0
AVG
Gross Margin
►
78.5%
Number of Patents
►
9.00
Revenue
Patents to Expire in next 5 years
Number of Drugs
R&D/Sales Ratio
Research and Development Expense
Net Income
Operating Income
INCOME STATEMENT (
See all
)
Revenue
►
21.1B
AVG
EBITDA
►
2.04B
AVG
Net Income
►
-216M
VERY LOW
Revenue Growth
►
3.7%
AVG
Net Income Growth
►
8.1%
AVG
Operating Margin
►
5.8%
AVG
Net Margin
►
-1%
AVG
Revenue, Net Income, and Net Margin
Revenue, Gross Profit, and Gross Margin
Operating Income
Ebit
Income Before Taxes
Net Income from Continuing Ops
Interest vs Continuing Income
Interest Coverage
Operating Expenses
Research & Development
SG&A
Amortization & Depreciation
BALANCE SHEET (most recent quarter) (
See all
)
Debt / Equity
►
1.74
HIGH
Current Ratio
►
1.95
AVG
Quick Ratio
►
1.43
AVG
Interest Coverage Ratio
►
4.33
AVG
Book Value Per Share
►
8.73
Cash Per Share
►
3.39
Loading...
STOCK SUMMARY
Open
36.04
Day Range
36.00
-
36.70
52 Week Range
27.21
-
40.78
Volume
7.32M
Avg Volume (3 mo)
6.68M
Shares Outstanding
1.15B
Market Cap
42.0B
VALUATION
Price to Earnings (P/E)
►
-178
Price to Book (P/B)
►
3.89
AVG
Price to Sales (P/S)
►
1.83
AVG
Return on Assets (ROA)
►
0.2%
AVG
Return on Equity (ROE)
►
-1.8%
AVG
EV/EBITDA
►
24.0
VERY HIGH
Dividend Yield
5.8%
VERY HIGH
ANALYST RECOMMENDATIONS
OWNERSHIP
Net Insider Buying 3mo
0%
Net Insider Buying 6mo
0%
Net Insider Buying 1yr
0%
Held by insiders
12%
Held by institutions
51.5%